AVTR

Avantor, Inc.

Fundamental data last updated:October 29, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.

 


VALUATION

P/E

-20.53

Market Cap ($M USD)

$11.64B

Forward P/E

21.15

PEG

2.13

PRICE TO SALES

1.78

PRICE TO BOOK

2.07

EV / EBITDA

120.02

5-Year Average P/E

Free Cash Flow Yield

3.90%

DCF Value

$18.24

Graham Number

N/A

Price to FCF

25.61

EV to FCF

33.07

Earnings Yield

-4.96%

FCF Yield

3.90%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.85

Next Year EPS Growth Estimate

$0.81

Next Year Revenue Growth Estimate

$6.59B

Return on Equity (ROE)

-10.34%

FREE CASH FLOW

Operating Margin

-4.35%

Debt-to-Equity

0.66

Piotroski F-Score

5

Altman Z-Score

1.98

Return on Invested Capital (ROIC)

-2.79%

Current Ratio

1.78

Quick Ratio

1.18

Net Debt to EBITDA

27.06

Interest Coverage

-1.60

Gross Profit margin

31.83%

FCF PER SHARE

$0.67

REVENUE PER SHARE

$9.70

Gainseekers Quantitative Analysis

Summary

Avantor, Inc. is trading at a significant discount to its DCF value, suggesting a potential mispricing by the market. The Forward P/E of 7.45 indicates optimism for future earnings, yet the negative Earnings Yield and Altman Z-score of 1.15 raise red flags about financial distress and growth sustainability. Despite a robust consensus target price, the current valuation metrics paint a picture of a company struggling with profitability. The market seems to be pricing in substantial risk, possibly due to its negative ROIC and operating margin.

AI Exposure / Tech Reliance

Operating within the Medical Instruments & Supplies industry, Avantor is well-positioned to leverage AI and tech advancements. The healthcare sector is increasingly reliant on data-driven solutions, and Avantor's focus on innovation could enhance its operational efficiency. However, its ability to adapt swiftly to tech shifts remains crucial for maintaining competitiveness.

The Bull Case

For the value or GARP investor, Avantor presents a compelling opportunity. The Piotroski F-Score of 6 suggests moderate financial health, while a strong FCF Yield of 7.74% indicates efficient cash generation. Despite a negative ROIC, the company's ability to convert revenue into free cash flow could signal underlying pricing power. These factors, combined with a reasonable Price to FCF ratio, make it an attractive prospect for those seeking undervalued growth.

The Bear Case

Avantor's financial landscape is marred by structural weaknesses. The negative EPS and operating margin highlight severe profitability issues, while the EV to EBITDA ratio of 41.43 suggests overvaluation. With a Price/Book ratio hovering around 1.01, the stock appears fairly valued, yet its proximity to the 52-week high raises concerns about technical overextension. These factors, coupled with poor interest coverage, underscore significant financial risk.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$12.25

Institutional Ownership %

1-Year Beta

0.94

Insider Buying % (6 Mo)

Distance to 52-Week High

1.37%

Distance to 52-Week Low

57.80%

EARNINGS SURPRISE %

9.66%

50-DAY SMA

$15.19

200-DAY SMA

$11.08

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.